Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1996-11-27
2000-10-24
Duffy, Patricia A.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
436501, 436 912, 436811, 536 2433, C12Q 168, C12P 1934
Patent
active
061365300
ABSTRACT:
The presence of a restriction site in the gene for apolipoprotein CI (APOCI) is a risk factor for Alzheimer's disease. The invention involves determining the presence of the restriction site in biological samples from patients suspected to be at risk for Alzheimer's disease. The presence of the restriction site indicates that the patient may be at higher risk for the disease; those who are heterozygotes may be at intermediate risk; while those lacking the site are at a lesser risk for the disease. PCR amplification and the use of improved oligonucleotide primers specific to the region surrounding the restriction site as well as digestion with the restriction enzyme may be used to determine the presence of the site. APOCI provides a genetic marker for Alzheimer's disease that is distinct from APOE4. The methods disclosed provide a more accurate and definitive screening technique for the early identification of Alzheimer's disease compared to screening of APOE4 alone in some populations.
REFERENCES:
patent: 4683202 (1987-07-01), Mullis
patent: 5434050 (1995-07-01), Maggio et al.
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5508167 (1996-04-01), Roses et al.
Smit et al, Biochem and Biophysical Research Communications, 152(3):1282-1288, 1988.
Yu et al, Am. J. Hum. Genet. 54:631-642, 1994.
Templeton, A.R, Genetics, 140:403-409, May 1995.
Poduslo et al, Neuroscience Letters, 201:81-83, 1995.
Poduslo et al, Society for Neuroscience, 21(1-3):1487, 1995.
Poduslo et al, Society for Neuroscience, 22(1-3):199, 1996.
Crawford et al, Neurobiology of Aging, 17(Suppl.):S124-S125, 1996.
Patentability Search for APOCI Allele.
New York Times, Nov. 1995 (exact date unknown).
Wall Street Journal, Aug. 15, 1995.
Andrew, et al., "DNA Analysis of Distinct Populations Suggests Multiple Origins for the Mutation Causing Huntington Disease," Clin Genet, 43:286-294, 1993.
Caracciolo, et al., "Lineage-Specific Requirement of c-abl Function in Normal Hematopoiesis," Science, 245:1107, 1989.
Chartier-Harlin, et al., "Apolipoprotein E4, .epsilon.4 Allele as a Major Risk Factor for Sporadic Early and Late-Onset Forms of Alzheimer's Disease: Analysis of the 19q13.2 Chromosomal Region," Human Molecular Genetics, 3(4):568-574, 1994.
Farrer, L.A. and Cupples, L.A., "Estimating the Probability for Major Gene Alzheimer Disease," Am. J. Hum. Genet., 54:374-383, 1994.
Frossard, et al., "Human Apolipoprotein CI (ApoC1) Gene Locus: BgII Dimorphic Site," Nucleic Acids Research, 15(3):1344, 1987.
Frossard, et al., "Human Apolipoprotein CI (apoC1) Gene Locus: DraI Dimorphic Site," Nucleic Acids Research, 15(4) :1884, 1987.
Goddard, et al., "Toward Localization of the Werner Syndrom Gene by Linkage Disequilibrium and Ancestral Haplotyping: Lessons Learned from Analysis of 35 Chromosome 8p11.1-21.1 Markers," Am. J. Hum. Genet., 58:1286-1302, 196.
Kamino, et al., "Genetic Association Study Between Senile Dementia of Alzheimer's Type and APOE/C1/C2 Gene Cluster," Gerontology, 42(Suppl 1) :12-19, 1996.
Lauer, et al., "Two Copies of the Human Apolipoprotein C-I Gene Are Linked Closely to the Apolipoprotein E Gene," Journal of Biological Chemistry, 263(15) :7277-7286, 1998.
Saiki, et al., "Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase," Science, 239 :487-491, 1988.
Sanger, et al., "DNA Sequencing with Chain-Terminating Inhibitors," Proc. Natl. Acad. Sci. USA, 74(12) :5463-5467, 1977.
Schellenberg, et al., "Genetic Association and Linkage Analysis of the Apolipoprotein CII Locus and Familial Alzheimer's Disease," Annals of Neurology, 31(2) :223-227, Feb. 1992.
Sehayek, et al., "Mechanisms of Inhibition by Apolipoprotein C of Apolipoprotein E-Dependent Cellular Metabolism of Human Triglyceride-Rich Lipoproteins Through the Low Density Lipoprotein Receptor Pathway," Journal of Biological Chemistry, 266(27) :18259-18267, Sep. 1991.
Shulman, et al., "The Complete Amino Acid Sequence of C-I (ApoLp-Ser), an Apolipoprotein from Human Very Low Density Lipoproteins," Journal of Bological Chemistry, 250(1) :182-190, Jan. 1975.
Simonet, et al., "Multiple Tissue-Specific Elements Control the Apolipoproten E/C-I Gene Locus in Transgenic Mice," Journal of Biological Chemistry, 266(14) :8651-8654, May 1991.
Smit, et al., "Apolipoprotein Gene Clustor on Chromosome 19: Definite Localization of the APOC2 Gene and the Polymorphic HpaI Site Associated with Type III Hyperlipoproteinemla,"Human Genetics, 78:90-93, 1998.
Strittmatter, et al., "Apolipoprotein E: High-Avidity Binding to .beta.-Amyloid and Increased Frequency of Type 4 Allele in Late-Onset Familial Alzheimer Disease," Proc. Natl. Acad. Sci. USA, 90:1977-1981, Mar. 1993.
Nillesen, et al., "Human ApoCI Hpal Restriction Site Polymorphism Revealed by the Polymerase Chain Reaction," Nucleic Acids Research, 18(11) :3428, 1990.
Weisgraber, et al., "Apolipoproten C-I Modulates the Interaction of Apolipoprotein E With .beta.-Migrating Very Low Density Lipoproteins (.beta.-VLDL) and Inhibits Binding of .beta.-VLDL to Low Density Lipoprotein Receptor-Related Protein," Journal of Biological Chemistry, 265(36) :22453-22459, Dec. 1990.
Duffy Patricia A.
Mayfield Denise L.
Texas Tech University Health Sciences Center
LandOfFree
Compositions and methods for assessing risk factors in Alzheimer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for assessing risk factors in Alzheimer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for assessing risk factors in Alzheimer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1962118